ArticleAllergy2017
Amb a 1 isoforms: Unequal siblings with distinct immunological features.
Article in Allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Common Ragweed Allergy Under Global Change Linking Invasion-Driven Aeroallergen Exposure with Molecular Sensitization and Allergic Airway Disease.Life (Basel, Switzerland) · 2026Review
- Amb a 1-Specific IgE in Heart Failure: A Translational Framework for Seasonal Risk, Endotyping, and Patient-Centered Management.Journal of clinical medicine · 2026Review
- Multi-country IgE reactivity determination of isoforms of theFrontiers in immunology · 2026Article
- Global Ragweed Allergy: Molecular Allergens and Integrated Control Strategies.Journal of asthma and allergy · 2025Review
- Heterogenous Induction of Blocking Antibodies against Ragweed Allergen Molecules by Allergen Extract-Based Immunotherapy Vaccines.Vaccines · 2024Article
- Insect Cell-Expressed Major Ragweed Allergen Amb a 1.01 Exhibits Similar Allergenic Properties to Its Natural Counterpart from Common Ragweed Pollen.International journal of molecular sciences · 2024Article
- [Sensitization characteristics of ragweed pollen in Beijing area].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2023Article
- Relationship between IgE Levels Specific for Ragweed Pollen Extract, Amb a 1 and Cross-Reactive Allergen Molecules.International journal of molecular sciences · 2023Article
- Complex IgE sensitization patterns in ragweed allergic patients: Implications for diagnosis and specific immunotherapy.Clinical and translational allergy · 2022Article
- Influence of the environment on ragweed pollen and their sensitizing capacity in a mouse model of allergic lung inflammation.Frontiers in allergy · 2022Article
- Chemical modification of ragweed extract results in an increased safety profile while maintaining immunogenicity.Allergy · 2021Article
- Identification and Physicochemical Characterization of a New Allergen fromInternational journal of molecular sciences · 2020Article
- Purification and biochemical characterization of Hel a 6, a cross-reactive pectate lyase allergen from Sunflower (Helianthus annuus L.) pollen.Scientific reports · 2020Article
- Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens.Clinical and translational allergy · 2020Article
- A hybrid of two major Blomia tropicalis allergens as an allergy vaccine candidate.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Article
- Initiating pollen sensitization - complex source, complex mechanisms.Clinical and translational allergy · 2020Review
- Cross-reactivity in allergy: A double-edged sword.Allergy · 2020Article
- Similar Allergenicity to DifferentMedicina (Kaunas, Lithuania) · 2019Article
- Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT.Clinical and translational allergy · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundRagweed pollen represents a major allergy risk factor. Ragweed extracts contain five different isoforms of the major allergen Amb a 1. However, the immunological characteristics of Amb a 1 isoforms are not fully investigated. Here, we compared the physicochemical and immunological properties of three most important Amb a 1 isoforms.
methodsAfter purification, the isoforms were physicochemically characterized, tested for antibody binding and induction of human T-cell proliferative responses. Their immunological properties were further evaluated in vitro and in vivo in a mouse model.
resultsAmb a 1 isoforms exhibited distinct patterns of IgE binding and immunogenicity. Compared to Amb a 1.02 or 03 isoforms, Amb a 1.01 showed higher IgE-binding activity. Isoforms 01 and 03 were the most potent stimulators of patients' T cells. In a mouse model of immunization, Amb a 1.01 induced higher levels of IgG and IgE antibodies when compared to isoforms 02 and 03. Interestingly, ragweed-sensitized patients also displayed an IgG response to Amb a 1 isoforms. However, unlike therapy-induced antibodies, sensitization-induced IgG did not show IgE-blocking activity.
conclusionThe present study showed that naturally occurring isoforms of Amb a 1 possess different immunogenic and sensitizing properties. These findings should be considered when selecting sequences for molecule-based diagnosis and therapy for ragweed allergy. Due to its high IgE-binding activity, isoform Amb a 1.01 should be included in diagnostic tests. In contrast, due to their limited B- and T-cell cross-reactivity patterns, a combination of different isoforms might be a more attractive strategy for ragweed immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.